Addition of a targeted therapy such as pertuzumab/trastuzumab or immunotherapy such as pembrolizumab to chemotherapy can also increase the response rate in HER2 overexpressed and triple negative breast cancer, respectively [4,5]. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.